VIRIDIAN THERAPEUTICS INC (VRDN)
US92790C1045 - Common Stock
Overall VRDN gets a fundamental rating of 3 out of 10. We evaluated VRDN against 588 industry peers in the Biotechnology industry. VRDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRDN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VRDN had negative earnings in the past year.
In the past year VRDN has reported a negative cash flow from operations.
In the past 5 years VRDN always reported negative net income.
In the past 5 years VRDN always reported negative operating cash flow.
1.2 Ratios
VRDN has a Return On Assets of -48.47%. This is comparable to the rest of the industry: VRDN outperforms 51.19% of its industry peers.
VRDN has a better Return On Equity (-53.78%) than 65.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.47% | ||
| ROE | -53.78% | ||
| ROIC | N/A |
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRDN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
The debt/assets ratio for VRDN is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.52 indicates that VRDN is not in any danger for bankruptcy at the moment.
VRDN's Altman-Z score of 9.52 is amongst the best of the industry. VRDN outperforms 85.84% of its industry peers.
VRDN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
VRDN has a Debt to Equity ratio (0.05) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.52 |
ROIC/WACCN/A
WACC9.17%
2.3 Liquidity
VRDN has a Current Ratio of 18.26. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN's Current ratio of 18.26 is amongst the best of the industry. VRDN outperforms 94.20% of its industry peers.
VRDN has a Quick Ratio of 18.26. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 18.26, VRDN belongs to the top of the industry, outperforming 94.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.26 | ||
| Quick Ratio | 18.26 |
3. Growth
3.1 Past
VRDN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.01%.
VRDN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.57%.
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -48.16% on average per year.
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-19.47%
Revenue 1Y (TTM)-82.57%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Revenue growth Q2Q-34.55%
3.2 Future
VRDN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.82% yearly.
The Revenue is expected to grow by 382.82% on average over the next years. This is a very strong growth
EPS Next Y12.85%
EPS Next 2Y5.96%
EPS Next 3Y15.72%
EPS Next 5Y22.82%
Revenue Next Year-28.75%
Revenue Next 2Y338.63%
Revenue Next 3Y653.97%
Revenue Next 5Y382.82%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRDN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VRDN's earnings are expected to grow with 15.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.96%
EPS Next 3Y15.72%
5. Dividend
5.1 Amount
VRDN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRIDIAN THERAPEUTICS INC
NASDAQ:VRDN (5/3/2024, 7:25:16 PM)
After market: 16.3 +0.9 (+5.84%)15.4
+0.82 (+5.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap982.83M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.47% | ||
| ROE | -53.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 18.26 | ||
| Quick Ratio | 18.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-82.57%
Revenue growth 3Y-33.13%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y